Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway

Citation
P. Chopin et al., Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway, J PHARM EXP, 288(2), 1999, pp. 798-804
Citations number
70
Categorie Soggetti
Pharmacology & Toxicology
Journal title
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
ISSN journal
00223565 → ACNP
Volume
288
Issue
2
Year of publication
1999
Pages
798 - 804
Database
ISI
SICI code
0022-3565(199902)288:2<798:EOAAAA>2.0.ZU;2-M
Abstract
The present study examined the influence of alpha-2 adrenoceptor ligands on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. The alpha-2 adrenoceptor agonists, clonidine and UK 14304, inhibited both the ipsilateral rotation induced by the indirect dop aminergic agonist, methylphenidate, and the contralateral circling induced by the direct dopaminergic agonist, apomorphine. In contrast, the alpha-2 a drenoceptor antagonists, idazoxan and (+/-)-efaroxan, enhanced the circling induced by either methylphenidate or apomorphine. The facilitating activit y of efaroxan was stereoselective because the (+)-enantiomer mimicked the e ffect of (+)-efaroxan, whereas the (-)-enantiomer was essentially inactive, thus indicating a mediation by alpha-e adrenoceptors. Upon administration alone, the above-mentioned compounds did not modify spontaneous circling be havior, except for UK 14304, which decreased, and (+)-efaroxan, which sligh tly increased, the ipsilateral rotation. We conclude that activation and an tagonism of alpha-2 adrenoceptors inhibit and enhance, respectively, the ci rcling behavior evoked by both direct and indirect dopaminergic agonists. A lthough a modulation of dopamine release may be involved in some of these d rug effects, the effects on apomorphine-induced circling indicate an influe nce of alpha-2 adrenoceptor compounds on nigrostriatal neurotransmission at sites downstream from the dopaminergic neurons themselves. These findings support the notion of a potential benefit of alpha-2 adrenoceptor antagonis ts in the treatment of Parkinson's disease.